Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR+
    • Governance
  • Contact

In the News

News & Media

News & Media

  • Press Releases
  • Events
  • In the News
Apr 28, 2023

Let’s Talk Rare Podcast - Interview with Xortx Therapeutics CEO, Dr Allen Davidoff discussing their journey from early development to potential launch

Mar 28, 2023

Rx for Biotech Podcast - New Therapies for Kidney Disease with XORTX Therapeutics CEO, Allen Davidoff, PhD

Mar 27, 2023

DocWire News - Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease

Mar 24, 2023

Pharmaphorum - Chronic kidney disease: Challenges and upcoming technologies

Mar 20, 2023

Kent's Kidney Stories - Episode 111: Dr. Allen Davidoff - Exploring New Therapies to Treat PKD

Mar 2, 2023

CheckRare - Plans for Two Phase 3 Studies Testing Oxypurinol To Treat ADPKD Announced

Feb 23, 2023

Empowered Patient Podcast - Slowing the Progression of Rare Polycystic Kidney Disease with Dr. Allen Davidoff XORTX Therapeutics

Feb 21, 2023

CheckRare - What Is Autosomal Dominant Polycystic Kidney Disease (ADPKD)?

Feb 2, 2023

Patient Worthy - Developing Novel Solutions for ADPKD: An Interview with XORTX Therapeutics’ CEO Dr. Allen Davidoff

Dec 1, 2022

Health Professional Radio - XORTX – Therapeutics for Progressive Kidney Disease

rss_feed RSS
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap